about
Clinical review of the management of fulminant clostridium difficile infection.Analysis of proline reduction in the nosocomial pathogen Clostridium difficile.Certification in infection control matters: Impact of infection control department characteristics and policies on rates of multidrug-resistant infections.Key research issues in Clostridium difficileProbiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review.A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.Hypervirulent strains of Clostridium difficile.Development and validation of a Clostridium difficile infection risk prediction model.Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive proteinPrevention and control of infections in the home.In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells.Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study.Clostridium difficile: how much do hospital staff know about it?
P2860
Q33375824-00A8B43E-24AF-4CAA-94CC-F814261E6101Q35220646-7F27D809-F15F-498F-A8C6-8C77DE01710CQ35898041-405A6090-7F0F-4141-8B57-181ABD8EBB1FQ36171102-A817780C-D53A-406F-BD70-5E6DEE0FC7B4Q36199514-97EBB22B-BCBB-4BFF-954B-0DF8C0A21E41Q36792749-8B43B8B2-ED8C-4E77-9251-E7DACDE32BAAQ36815464-0423B0A2-DFAA-4C2F-B72F-1AF75C312145Q36831098-46B352C2-BD8A-4920-8D3E-6DE44720F2D7Q37230159-9E2C60E9-1204-43BB-9F0C-1983F654DED4Q37495309-6918A505-9E10-4D94-9346-C6DC8AC2CC00Q38665033-AAC1C481-1AF6-472F-80E6-AF2E63C58873Q39792658-F43A0FCA-04AF-479B-8BB7-41A713EF7C6EQ40091474-37CB19E0-769F-453B-BC33-6F658059F40FQ42146543-B54C49D5-1684-42DC-A73C-4E21458985EA
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Clostridium difficile: a formidable foe.
@ast
Clostridium difficile: a formidable foe.
@en
type
label
Clostridium difficile: a formidable foe.
@ast
Clostridium difficile: a formidable foe.
@en
prefLabel
Clostridium difficile: a formidable foe.
@ast
Clostridium difficile: a formidable foe.
@en
P2093
P2860
P356
P1476
Clostridium difficile: a formidable foe.
@en
P2093
Anne Vibien
Anne-Marie Bourgault
Charles H Frenette
Louise Poirier
Mark A Miller
Michael D Libman
Mirabelle Kelly
Pierre J Laflamme
Pierre René
P2860
P356
10.1503/CMAJ.1040836
P407
P577
2004-07-01T00:00:00Z